PAREXEL CEO TO DISCUSS FACTORS DRIVING CHANGE IN PARTNER MODELS AT 16TH ANNUAL PARTNERSHIPS WITH CROS CONFERENCE
BOSTON, MA, April 9, 2007 — Josef von Rickenbach, Chairman and Chief Executive Officer of PAREXEL International Corporation (NASDAQ: PRXL), a leading global bio/pharmaceutical services provider, will participate in a CEO Roundtable at the 16th Annual Partnerships with CROs conference, to be held April 10 – 12, 2007 in Orlando, Florida. The roundtable discussion will address industry trends and challenges, business strategies, and the future state of the service provider sector, as well as evolving partner relationships with the bio/pharmaceutical industry.
The CEO Roundtable titled “Part I – The Provider Perspective: Shaping the Business to Meet Current and Future Sponsor Needs,” which will be held from 9:15 – 10:00 a.m. on Wednesday, April 11, will be the first of a two part morning keynote session, with the second session focusing on the sponsor perspective. The provider roundtable, moderated by Amgen’s Executive Director of Strategic Sourcing and Procurement Warren Myers, will include insights from Mr. von Rickenbach and senior executive leaders of other service provider organizations. “Part II – The Sponsor Perspective: Maturation of the Pharmaceutical Business: Operational Dynamics that Drive Outsourcing” will feature executives from bio/pharmaceutical companies.
For the past 25 years, clients have relied on PAREXEL to provide integrated clinical development, regulatory affairs consulting and commercialization services, as well as to offer technologies that expedite time-to-market. Attendees at the 16th Annual Partnerships with CROs conference can visit PAREXEL’s Booth #436 in the exhibit hall to discuss these capabilities.
PAREXEL is a sponsor of the 16th Annual Partnerships with CROs conference, a leading outsourcing and clinical development event. The conference brings together professionals from the bio/pharmaceutical industry and contract service organizations as well as clinical sites and other service providers. The program explores best practices for creating, managing, and sustaining clinical outsourcing partnerships to enable more efficient and safe trials that lead to new life-saving and life-extending treatments.
For more information about PAREXEL visit www.PAREXEL.com or Booth #436 at the 16th Annual Partnerships with CROs conference.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS) and integration services. Headquartered near Boston, Massachusetts, PAREXEL operates in 56 locations throughout 43 countries around the world, and has over 6,215 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company’s Quarterly Report on Form 10-Q for the period ended December 31, 2006 as filed with the SEC on February 9, 2007, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.